Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

Cognitive impairment in diabetes mellitus and hypertension, a possibility of correction

https://doi.org/10.14412/2074-2711-2016-3-48-52

Full Text:

Abstract

Objective: to evaluate cognitive functions in patients with type 2 diabetes mellitus (DM2) and hypertension and the efficacy of Ginkgo biloba extract Egb 761®.

Patients and methods. 120 patients with DM2 and 50 hypertensive patients with no complications or a history of stroke and/or myocardial infarction, without active complaints of hypomnesia and other cognitive functions were examined. The exclusion criteria were prior stroke and/or myocardial infarction; clinically significant diseases of the peripheral arteries and major arteries of the head; DM2 decompensation; glomerular filtration rate <60 ml/min; proliferative retinopathy; and other endocrine diseases. The investigators used the following methods for the evaluation of cognitive functions: the Mini-Mental State Examination, the Montreal Cognitive Assessment, and the hand- eye coordination test (Parts A and B).

Results and discussion. 85% of the patients with DM2 were found to have cognitive impairments (CI): disorders of attention, short-term memory, and thinking speed. Out of them, 82.5% had moderate CI and 2.5% had dementia. 30% of the hypertensive patients were diagnosed as having moderate CIs and 10% had dementia. At the same time, the degree of CI was higher in the patients with MD2 than in those with hypertension. The use of Egb 761® 240 mg/day for 3 months had a statistically significant positive impact on cognitive functions (improvements in short-term memory, concentration, and thinking speed) and everyday activity.

Conclusion. The authors consider that CIs are the first sign of encephalopathy in DM2. It is also noted that DM2 has a more pronounced impact on cognitive functions than hypertension. Egb 761® can be used as an effective drug to treat CI in these diseases.

About the Authors

I. Ch. Khairullin
Kazan (Volga) Federal University. Kazan, Russia 18, Kremlevskaya St., Kazan 420008, Republic of Tatarstan
Russian Federation


R. G. Esin
Kazan (Volga) Federal University. Kazan, Russia 18, Kremlevskaya St., Kazan 420008, Republic of Tatarstan Kazan State Medical University, Ministry of Health of Russia, Kazan, Russia 49, Butlerov St., Kazan 420012, Republic of Tatarstan
Russian Federation


O. R. Esin
Kazan (Volga) Federal University. Kazan, Russia 18, Kremlevskaya St., Kazan 420008, Republic of Tatarstan
Russian Federation


References

1. Дамулин ИВ. Сосудистая деменция: патогенез, диагностика и лечение. Фарматека. 2010;(7):13-8. [Damulin IV. Vascular dementia: pathogenesis, diagnosis and treatment. Farmateka. 2010;(7):13-8. (In Russ.)].

2. Парфенов ВА. Дифференциальный диагноз и лечение дисциркуляторной энцефалопатии. Consilium-medicum. 2013;(9):28-32. [Parfenov VA. Differential diagnosis and treatment of dyscirculatory encephalopathy. Consilium-medicum. 2013;(9):28-32. (In Russ.)].

3. O'Brien J, Erkinjuntti T, Reisberg T, et al. Vascular cognitive impairment. The Lancet Neurology. 2003;2(2):89-98. doi:10.1016/s1474-4422(03)00305-3.

4. Есин РГ, Хайруллин ИХ, Есин ОР и др. Диабетическая энцефалопатия: патогенез, клинические проявления, подходы к терапии. Клиницист. 2012;(3):10-6. [Esin RG, Khairullin IKh, Esin OR, et al. Diabetic encephalopathy: pathogenesis, clinical manifestations, approaches to therapy. Klinitsist. 2012;(3):10-6. (In Russ.)]. doi:10.17650/1818-8338-2012-3-4-10-16

5. Хуторная ОЕ, Бреговский ВБ, Демина АГ, Карпова ИА. Гетерогенность болевой диабетической полинейропатии и дифференцированный подход к ее лечению. Сахарный диабет. 2013;(2):62-6. [Khutornaya OE, Bregovskii VB, Demina AG, Karpova IA. Heterogeneity of painful diabetic neuropathy and differential approach to its treatment. Sakharnyi diabet. 2013;(2):62-6. (In Russ.)]. doi:10.14341/2072-0351-3757

6. Dyck P, Albers J, Andersen H, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes/Metabolism Research and Reviews. 2011;27(7):620-8. doi:10.1002/dmrr.1226.

7. Miles W, Root H. Psychologic tests applied in diabetic patients. Arch Intern Med. 1922; (30): 767-70.

8. Строков ИА, Захаров ВВ, Строков КИ. Диабетическая энцефалопатия. Неврология, нейропсихиатрия, психосоматика. 2012;4(2S):30-40. [Strokov IA, Zakharov VV, Strokov KI. Diabetic encephalopathy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(2S):30-40. (In Russ.)]. doi:10.14412/ 2074-2711- 2012-2506

9. Товажнянская ЕЛ, Безуглова ИО, Наврузов МБ, Балковая НС. Умеренные когнитивные нарушения при сахарном диабете 2- го типа. Международный медицинский журнал. 2012;(1):6-9. [Tovazhnyanskaya EL, Bezuglova IO, Navruzov MB, Balkovaya NS. Mild cognitive impairment in diabetes of the 2nd type. Mezhdunarodnyi meditsinskii zhurnal. 2012;(1):6-9. (In Russ.)].

10. Myint A. Alzheimer’s Disease and Type 2 Diabetes mellitus: risk factors and effectiveness of antidiabetic agents in treatment of Alzheimer’s disease. SJCM. 2013;2(3):114. doi:10.11648/j.sjcm. 20130203.20.

11. Umegaki H. Type 2 diabetes as a risk factor for cognitive impairment: current insights. Clin Interv Aging. 2014 Jun 28;9:1011-9. doi: 10.2147/CIA.S48926. eCollection 2014.

12. Vijayakumar T, Sirisha G, Farzana B, Dhanaraju M. Mechanism linking cognitive impairment and diabetes mellitus. European Journal of Applied Sciences. 2012;4(1):1-5.

13. Хайруллин ИХ, Есин РГ, Поздняк АО. Возможности коррекции когнитивного снижения у пациентов с сахарным диабетом 2 типа. Журнал неврологии и психиатрии им. С.С.Корсакова. 2014;(9):19-23. [Khairullin IKh, Esin RG, Pozdnyak AO. Possibilities of correction of cognitive impairment in patients with diabetes mellitus type 2. Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2014;(9):19-23. (In Russ.)].

14. Folstein M, Folstein S, McHugh P. «Mini-Mental State»: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98.

15. MoCA version august 18, 2010© Nasreddine Z. www.mocatest.org 16. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002 Mar;8(3):448-60. doi:10.1017/s1355617702813248.

16. Corrigan J, Hinkeldey M. Relationships between parts A and B of the Trail Making Test. J Clin Psychol. 1987 Jul;43(4):402-9.

17. Хафизьянова РХ, Бурыкин ИМ, Алеева ГН. Математическая статистика в экспериментальной и клинической фармакологии: монография. Казань: Медицина; 2006. [Khafiz'yanova RKh, Burykin IM, Aleeva GN. Matematicheskaya statistika v eksperimental'noi i klinicheskoi farmakologii: monografiya [Mathematical statistics in experimental and clinical pharmacology: monograph]. Kazan': Meditsina; 2006.]

18. Реброва ОЮ. Статистический анализ медицинских данных. Применение пакета прикладных программ Statistica. Москва: Медиа Сфера; 2002. [Rebrova OYu. Statisticheskii analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm Statistica [Statistical analysis of medical data. Application of software package Statistica]. Moscow: Media Sfera; 2002.]

19. Кадыков АС, Шахпаровнова НВ, Кадыков АВ. Гипертоническая энцефалопатия: узловые точки диагностики и лечения. Consilium medicum. 2013;(2):36-9. [Kadykov AS, Shakhparovnova NV, Kadykov AV. Hypertensive encephalopathy: the key points of diagnosis and treatment. Consilium medicum. 2013;(2):36-9. (In Russ.)].

20. Wysocki M, Luo X, Schmeidler J, et al. Hypertension is Associated With Cognitive Decline in Elderly People at High Risk for Dementia. Am J Geriatr Psychiatry. 2012 Feb;20(2):179-87. doi: 10.1097/JGP.0b013e31820ee833.

21. Goldstein F, Levey A, Steenland N. High blood pressure and cognitive decline in mild cognitive impairment. J Am Geriatr Soc. 2013 Jan;61(1):67-73. doi: 10.1111/jgs.12067. Epub 2013 Jan 10.

22. Наприенко МВ, Есин РГ, Мухаметова ЭР и др. Танакан — мультимодальный цитопротектор для общемедицинской практики (часть 1). Журнал неврологии и психиатрии им. С.С.Корсакова. 2015;(11):146-51. [Naprienko MV, Esin RG, Mukhametova ER, et al. Tanakan – multimodal cytoprotector for General medical practice (part 1). Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2015;(11):146-51. (In Russ.)]. doi: 10.17116/jnevro2015115111146-151

23. Есин РГ, Наприенко МВ, Мухаметова ЭР и др. Танакан – мультимодальный цитопротектор для общемедицинской практики (часть 2). Журнал неврологии и психиатрии им. С.С.Корсакова. 2015;(12):157-62. [Esin RG, Naprienko MV, Mukhametova ER i dr. Tanakan – multimodal cytoprotector for General medical practice (part 2). Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova. 2015;(12):157-62. (In Russ.)]. doi:10.17116/jnevro2015115112177-182


For citation:


Khairullin I.C., Esin R.G., Esin O.R. Cognitive impairment in diabetes mellitus and hypertension, a possibility of correction. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(3):48-52. (In Russ.) https://doi.org/10.14412/2074-2711-2016-3-48-52

Views: 343


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)